Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeCost of RevenueEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest ExpensesNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax Rate
Others
Ratios

Arcutis Biotherapeutics (ARQT) EPS (Basic) (2020 - 2025)

Arcutis Biotherapeutics has reported EPS (Basic) over the past 6 years, most recently at $0.13 for Q4 2025.

  • Quarterly results put EPS (Basic) at $0.13 for Q4 2025, up 262.5% from a year ago — trailing twelve months through Dec 2025 was -$0.14 (up 87.83% YoY), and the annual figure for FY2025 was -$0.13, up 88.79%.
  • EPS (Basic) for Q4 2025 was $0.13 at Arcutis Biotherapeutics, up from $0.06 in the prior quarter.
  • Over the last five years, EPS (Basic) for ARQT hit a ceiling of $0.13 in Q4 2025 and a floor of -$1.89 in Q3 2022.
  • Median EPS (Basic) over the past 5 years was -$0.74 (2021), compared with a mean of -$0.74.
  • Biggest five-year swings in EPS (Basic): crashed 81.01% in 2021 and later surged 262.5% in 2025.
  • Arcutis Biotherapeutics' EPS (Basic) stood at -$1.43 in 2021, then rose by 20.28% to -$1.14 in 2022, then soared by 48.25% to -$0.59 in 2023, then skyrocketed by 86.44% to -$0.08 in 2024, then surged by 262.5% to $0.13 in 2025.
  • The last three reported values for EPS (Basic) were $0.13 (Q4 2025), $0.06 (Q3 2025), and -$0.13 (Q2 2025) per Business Quant data.